INTRODUCTION
============

Non-ST-elevation acute coronary syndrome (NSTE-ACS) includes non-ST-elevation myocardial infarction (NSTEMI) and unstable angina (UA), which accounted for more than two thirds of all cases of acute coronary syndrome (ACS) in the United States in 2009 ([@b1-cln_69p398]). Furthermore, cardiovascular disease, including NSTE-ACS, still remains the leading cause of mortality worldwide ([@b2-cln_69p398]). NSTE-ACS represents an increasingly frequent cause of hospital admission, as it is the most frequent presentation of coronary instability in patients with prior cardiac events or coronary revascularizations ([@b3-cln_69p398]). Compared with ST-elevation myocardial infarction (STEMI), NSTE-ACS is usually associated with a partial or transient coronary obstruction that results in a temporary reduction in coronary blood flow, and microemboli have also been implicated in the pathophysiology of NSTE-ACS ([@b4-cln_69p398]). Recognizing the difference between NSTE-ACS and STEMI is critical when developing therapeutic strategies for NSTE-ACS. For instance, thrombolytic management is not indicated in NSTE-ACS management ([@b5-cln_69p398]). Experimental data from randomized clinical trials have clearly demonstrated the efficacy of conservative or invasive approaches in the above mentioned patients ([@b6-cln_69p398]-[@b8-cln_69p398]). In clinical practice, physicians caring for NSTE-ACS patients are faced with immediate decisions about substantially different therapeutic strategies that may significantly affect short- and long-term outcomes ([@b9-cln_69p398]).

An increasing number of studies havedemonstrated that an invasive treatment strategy rather than a conservative approach improves the outcomes of NSTE-ACS patients ([@b6-cln_69p398]-[@b8-cln_69p398],[@b10-cln_69p398]-[@b16-cln_69p398]). However, some studies have shown that a conservative strategy provides the same benefit as an invasive strategy for NSTE-ACS patients, and clearly shown that the efficacy of invasive treatment was not definite ([@b17-cln_69p398],[@b18-cln_69p398]).

According to the 2012 American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines ([@b19-cln_69p398]), medical therapy remains a cornerstone in managing patients with NSTE-ACS, and we found that in the above mentioned studies that demonstrated the benefit of an invasive strategy, the administration of antithrombotics (antiplatelets or oral anticoagulants) statins was the primary step prior to interventional therapy. However, in the conservative treatment group, the NSTE-ACS patients also received interventional therapy during the index hospitalization when medical therapy failed or if substantial residual ischemia was documented in some of the randomized control trials (RCTs) ([@b6-cln_69p398],[@b8-cln_69p398],[@b9-cln_69p398],[@b18-cln_69p398],[@b20-cln_69p398],[@b21-cln_69p398]).

It is necessary to clearly distinguish between the different efficacies for invasive and conservative strategies for NSTE-ACS patients. Therefore, we performed the present meta-analysis to analyze the benefits between invasive and conservative strategies for NSTE-ACS patients.

METHODS
=======

We followed the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines ([@b22-cln_69p398]) for randomized clinical trials and the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines ([@b23-cln_69p398]) for observational cohort studies in the present meta-analysis.

Study search strategy
---------------------

Accessing the PubMed database, we conducted a literature search for research papers published from 1990 to November 2012. The following search terms and keywords were used: "non-ST-elevation myocardial infarction", "unstable angina", "acute coronary syndromes", "invasive strategy", and "conservative strategy". In addition, we also manually checked the reference list of each article. The main focus of the study was RCTs and observational cohort studies (OCS). We excluded those research papers with the following keywords: "review", "review literature", "review of reported cases", "review, academic", "review, multicase", "review, tutorial", "case reports", "congresses", "interview", "overall", "comment", "letter", "practice guideline", "scientific integrity review", "news", "newspaper article", and "address". The search was limited by the search words of "\>19 years", "Publication Date from 1990/01/01 to 2012/11/01", "English", and "Human".

Study Selection
---------------

Eligible patients had experienced NSTE-ACS (i.e., NSTEMI or UA) that was treated with invasive or conservative treatment during the admission. The NSTE-ACS diagnosis was based on the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) Guidelines 2012 for NSTE-ACS ([@b19-cln_69p398]). In our present meta-analysis, the invasive group contained patients who underwent cardiac catheterization, diagnostic angiography, coronary artery bypass graft (CABG) surgery, and intra-aortic balloon pump (IABP) performed during the index hospitalization with or without revascularization; the conservative group contained patients who did not undergo catheterization, angiography, CABG, or IABP during the index hospitalization. Conservative therapy consists of vigorous anti-ischemic therapy with nitrates, statins, β-blockers, and (sometimes) calcium channel blockers, as well as antithrombotic therapy with aspirin, clopidogrel, or ticagrelor, and low molecular weight heparin (LMWH) while the patients are in the hospital. In ACS patients, antithrombotics can effectively inhibit thrombus formation and coagulation, and stains can play important roles in stabilizing plaque, inhibiting vascular endothelial inflammation, improving endothelial function, and reducing cholesterol levels. The main endpoints were death from all causes at 30 days and 1 year. Patients who received both conservative and interventional therapy in the hospital were excluded.

We originally planned to perform the meta-analysis in two parts: RCTs and OCS analyzed in two separate meta-analyses; however, there was only one RCT included in the present work ([@b17-cln_69p398]). For this reason, we retrospectively analyzed all included studies at two different time points (30 days and 1 year) by meta-analysis.

Data Extraction
---------------

In addition to information about the study design, characteristics, and sample size, we extracted the following data from the research papers: the actual number of survivors and non-survivors and corresponding cohort sizes. The main outcome variables were 30-day and 1-year survival rates.

Statistical Analysis
--------------------

We performed the meta-analysis using Comprehensive Meta-analysis software, version 2.2.064 (Biostat, Englewood, NJ, USA). Risk ratios (RR) and 95% confidence intervals (95% CI) were calculated for each study and pooled with a random effects model because the heterogeneity of all meta-analyses could not be ignored, as indicated by an *I*^2^ statistics above 50% and a *p*\<0.10. Heterogeneity among studies was formally assessed by the *Q* and *I*^2^ statistics. Publication bias was assessed by calculating the fail-safe number (Nfs) ([@b24-cln_69p398]) according to the formula Nfs.05 = (ΣZ/1.645)^2^-N. A fail-safe number indicates the number of non-significant, unpublished studies that would need to be added to a meta-analysis to reduce the overall statistically significant results to non-significance. If the number is large relative to the number of observed studies, the summary conclusions are fairly reliable. All analyses were performed using the SPSS 17.0 software package (SPSS, Inc., Chicago, IL, USA), and *p-*values\<0.05 were considered to be statistically significant.

RESULTS
=======

Seven studies were included in the meta-analysis; one study was an RCT, and the other six were OCS; the total number of patients in all seven studies was 61,652 ([@b11-cln_69p398]-[@b17-cln_69p398]) ([Figure 1](#f1-cln_69p398){ref-type="fig"}) ([Table 1](#t1-cln_69p398){ref-type="table"}).

There were three studies in the first meta-analysis ([@b11-cln_69p398],[@b14-cln_69p398],[@b17-cln_69p398]); we used all-cause mortality at 30 days as the primary endpoint, and 9,315 patients were included in the systematic review. After the data were analyzed, we found that an invasive strategy was associated with a statistically significant 15.6% decreased mortality (RR, 0.839 \[95% CI, 0.648-1.086\]) compared to conservative strategy during the 30 days after hospital discharge ([Figure 2](#f2-cln_69p398){ref-type="fig"}). In this meta-analysis, we used a random-effects model to consider the effect of heterogeneity among the studies (*Q* = 14.77, *p* = 0.001, *I*^2^ = 86.46%). The calculation for the Nfs.05 is 20.97, which suggests that there need to be 21 studies with a negative conclusion to reverse the conclusion. The conclusion from this meta-analysis is convincing, with little risk of publication bias.

In the next systematic review, the seven studies were included in the meta-analysis. We compared the mortality of patients treated with an invasive strategy and a conservative strategy for one year after hospital discharge. Of the 37,017 patients with NSTE-ACS who received invasive treatments and were discharged, there were 1,317 patients who died within one year. However, 24,635 patients received conservative treatment and were discharged and 3,254 patients died within one year. After the data were pooled, we found that invasive therapy significantly reduced mortality by 73.1% within one year after discharge (RR, 0.276 \[95% CI, 0.259-0.294\]) compared to conservative therapy ([Figure 3](#f3-cln_69p398){ref-type="fig"}). In the second meta-analysis, we also used a random-effects model to consider the effect of heterogeneity among the studies (*Q* = 110.7, *p*\<0.001, *I*^2^ = 94.58%). The sensitivity analysis reveals that 2,505 negative studies have been missed to reverse the statistical significance (Nfs.05 = 2505). The conclusion from the second meta-analysis is convincing, and the publication bias could be neglected.

DISCUSSION
==========

NSTE-ACS is responsible for approximately 1 million admissions to U.S. hospitals and twice as many to European hospitals each year and is associated with an in-hospital mortality rate of approximately 5% ([@b25-cln_69p398]). Worldwide, more than 4 million people each year are estimated to have a NSTEMI, and long-term mortality is higher in patients with NSTE-ACS than in those with ST-elevation acute coronary syndrome (STE-ACS) ([@b26-cln_69p398],[@b27-cln_69p398]). In 2012, the ACCF/AHA published an update to their 2011 guidelines for the management of patients with NSTE-ACS ([@b19-cln_69p398],[@b28-cln_69p398]). According to the new guidelines, selecting either invasive or conservative strategy is one of the most important decisions that must be made in managing NSTE-ACS patients. The ACC/AHA guidelines continue to support an early invasive strategy in patients with high-risk NSTE-ACS without serious comorbidities or contraindications to angiography; in contrast, an early conservative approach should be selected for low-risk patients.

The results of our present study were consistent with the new 2012 guidelines, and the two systematic meta-analyses showed that compared to a conservative strategy, an invasive strategy is associated with reduced short- and long-term mortality in patients with NSTE-ACS after hospital discharge.

Meta-analyses are statistical tools for pooling existing evidence; therefore, we considered the strength of the evidence from all seven studies ([@b11-cln_69p398]-[@b17-cln_69p398]). We searched and analyzed those articles addressing the treatment strategies for NSTE-ACS. Furthermore, we studied the details of the related studies according to the 2012 guidelines ([@b19-cln_69p398]); these studies include well-known studies such as the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease II) ([@b4-cln_69p398]), the RITA 3 (Randomized Intervention Trial of Unstable Angina 3) trial ([@b8-cln_69p398]), TACTICS-TIMI 18 (Treat angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction 18) trial ([@b7-cln_69p398]), ICTUS (Invasive *vs* Conservative Treatment in Unstable Coronary Syndromes) trial ([@b29-cln_69p398]), TIMI IIIB (Thrombolysis in Myocardial Infarction IIIB) ([@b30-cln_69p398]), MATE (Medicine *vs* Angiography in Thrombolytic Exclusion) ([@b31-cln_69p398]), and VINO (Value of First Day Angiography/Angioplasty In Evolving Non-ST Segment Elevation Myocardial Infarction) ([@b32-cln_69p398]). Based on the above mentioned studies, we found that an invasive strategy could improve the short- or long-term survival rates of NSTE-ACS patients compared to a conservative strategy. In addition, a related meta-analysis demonstrated that an invasive strategy had comparable benefits in men and high-risk women for reducing the composite end point of death, MI, or re-hospitalization with NSTE-ACS ([@b33-cln_69p398]).

In our present work, we did not distinguish between gender, age, risk factors, and complications for the two strategies; however, we focused on the all-cause mortality at 30 days and 1 year after hospital discharge. At the same time, we strictly limited the definition of the invasive and conservative strategies. The invasive group contained patients who underwent cardiac catheterization during the index hospitalization with or without revascularization; in contrast, patients who did not receive catheterization in the hospital were included in the conservative group. Catheterization included angiography and percutaneous coronary intervention; moreover, patients who underwent CABG surgery and IABP in the hospital were included in the invasive group. Our purpose was to assess whether a particular strategy decreased all-cause mortality in NSTE-ACS patients. Boden et al. ([@b17-cln_69p398]) demonstrated that some NSTE-ACS patients in the conservative group also received interventional therapy, but we analyzed the total details of the study and regrouped the patients into the conservative or invasive management groups; then, we retrospectively analyzed the data and eliminated the interference from the two therapies with one another. Although the William et al. study was a RCT, we included it in the present work after addressing the interfering factors. Thus, seven studies were included in our meta-analysis.

While analyzing our data, we assessed other reviews that compared the effectiveness of both strategies in NSTE-ACS patients. These reviews include Núñez et al. ([@b9-cln_69p398]), Boden ([@b34-cln_69p398],[@b35-cln_69p398]), Neumann et al. ([@b36-cln_69p398]), Choudhry et al. ([@b37-cln_69p398]), O′Donoghue et al. ([@b33-cln_69p398]), Hoenig et al. ([@b38-cln_69p398],[@b39-cln_69p398]), Navarese et al. ([@b40-cln_69p398]), and Damman P et al. ([@b41-cln_69p398]) Based on these reviews, we found that over the past 10 years, there is still controversy regarding invasive *versus* conservative strategy in NSTE-ACS patients. Compared with a conservative strategy for NSTE-ACS patients, some studies reported that an invasive therapy provided comparable benefits and reduced the rates of fatal or nonfatal re-infarction and hospital readmission but not all-cause mortality ([@b9-cln_69p398],[@b33-cln_69p398],[@b35-cln_69p398],[@b37-cln_69p398]). However, other studies found that an invasive strategy was not related to improvements in long-term survival and reduced the rate of revascularization compared with conservative management ([@b34-cln_69p398],[@b36-cln_69p398],[@b40-cln_69p398],[@b41-cln_69p398]).

Furthermore, the above mentioned studies did not strictly distinguish between or define conservative and invasive strategies; for instance, the administration of antithrombotics was the primary step prior to interventional therapy in invasive strategy. However, in some RCTs, patients with NSTE-ACS in the conservative treatment group also received interventional therapy during the index hospitalization when medical therapy failed or if substantial residual ischemia was documented. Based on these facts, we defined the concept of conservative and invasive strategies strictly as described in our article and performed the meta-analysis based on these definitions.

Inspired by the above mentioned studies, we strictly redefined the conservative and invasive strategy and retrospectively analyzed seven studies. The NSTE-ACS patients who received interventional management in the hospital were included in the invasive group, whereas the other patients were placed in the conservative group. The main end-point events were 30-day and 1-year all-cause mortality. After performing two systematic meta-analyses, we found that invasive therapy improved the prognosis of patients with NSTE-ACS (compared with conservative therapy) and reduced the short- and long-term mortality.

We also noted that the results of the Boden et al. study ([@b17-cln_69p398]) demonstrated that conservative therapies could play more beneficial roles in NSTE-ACS patients than did invasive strategies. What are the reasons for the opposite results? We analyzed their findings in detail and further studied its quotation from Ferry et al. ([@b42-cln_69p398]) and found that the authors excluded 247 patients with high-risk ischemic complications (e.g., unstable angina after infarction, congestive heart failure that did not respond to medical therapy, cardiogenic shock, or symptomatic ventricular arrhythmia) during the first 48 hours after the onset of infarction. Moreover, the invasive theories, techniques and equipment were not then as well established as they are currently. With the development of modern percutaneous coronary intervention technology, invasive strategies show more benefit than conservative medical therapies in NSTE-ACS patients.

For patients with NSTE-ACS (NSTEMI/UA), an invasive strategy reduces short- and long-term all-cause mortality compared with a conservative strategy. An invasive strategy is preferable to a conservative strategy in treating NSTE-ACS. Of course, these results require validation in future RCTs.
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###### 

Characteristics of the included NSTE-ACS studies.

  Sources                                         Study Design    Number of Deaths/Patients who Underwent Invasive Treatment for 30 days   Number of Deaths/Patients who Underwent Conservative Treatment for 30 days   Number of Deaths/Patients who Underwent Invasive Treatment for 1 year   Number of Deaths/Patients who Underwent Conservative Treatment for 1 year
  ----------------------------------------------- --------------- ------------------------------------------------------------------------ ---------------------------------------------------------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------------------
  **OCS**                                                                                                                                                                                                                                                                                       
  Leslie et al., ([@b11-cln_69p398]) 2003^\*△^    Retrospective   100/4535                                                                 97/3362                                                                      181/4535                                                                309/3362
  Timm et al., ([@b12-cln_69p398]) 2007^△^        Prospective                                                                                                                                                           101/945                                                                 227/815
  Cindy et al., ([@b13-cln_69p398]) 2008^△^       Prospective                                                                                                                                                           55/1382                                                                 82/754
  Rogério et al., ([@b14-cln_69p398]) 2009^\*△^   Prospective     1/386                                                                    13/334                                                                       16/386                                                                  46/334
  Kouraki et al., ([@b15-cln_69p398]) 2011^△^     Prospective                                                                                                                                                           98/1215                                                                 185/771
  Joakim et al., ([@b16-cln_69p398]) 2011^△^      Prospective                                                                                                                                                           814/28112                                                               2381/18343
  **RCTs**                                                                                                                                                                                                                                                                                      
  William et al., ([@b17-cln_69p398]) 1998^\*△^   RCT             33/442                                                                   7/256                                                                        52/442                                                                  24/256

NSTE-ACS: non-ST-elevation acute coronary syndrome; RCT: randomized controlled trials. \* Included in the meta-analysis of all-cause mortality within 30 days for patients with NSTE-ACS. △ The seven studies included in the meta-analysis of all-cause mortality within 1 year for NSTE-ACS patients.
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